FOXP3 and neoplasm: The increased response to immunotherapy (anti-PD1 and anti-PDL1 antibodies) in this study is associated with the increased functionality of anti-tumor CD8 cells and a trend towards decreased tumor-suppressive FOXP3 T cells with the tumor microenvironment (Figure 7) [68,69].